Publication year
2013Source
Oncoimmunology, 2, 5, (2013), pp. e24271ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Tumorimmunology
Gynaecology
Paediatrics - OUD tm 2017
Journal title
Oncoimmunology
Volume
vol. 2
Issue
iss. 5
Page start
p. e24271
Subject
NCMLS 2: Immune Regulation; NCMLS 3: Tissue engineering and pathology; ONCOL 1: Hereditary cancer and cancer-related syndromes; ONCOL 2: Age-related aspects of cancer; ONCOL 3: Translational research; ONCOL 3: Translational research NCMLS 2: Immune Regulation; ONCOL 5: Aetiology, screening and detection; ONCOL 5: Aetiology, screening and detection NCMLS 2: Immune RegulationAbstract
The identification of growth and differentiation pathways that are responsible for the proliferation and survival of cancer stem cells (CSCs) has opened avenues for the discovery of novel therapeutic targets. In the initial phase of an anticancer immune response, T cells specific for tumor-associated antigens develop in patients and, at least under selected circumstances, are able to eliminate malignant cells. However, it remains unknown whether CSC-specific T cells are also operational. We found naturally occurring multifunctional CD4+ and CD8+ T cells specific for the stem cell marker OCT4 among the peripheral blood mononuclear cells (PBMCs) of both healthy individuals and ovarian cancer patients. Moreover, lymphocytes isolated from the ascites of patients affected by ovarian malignancies also contained OCT4-specific T cells. OCT4-reactive CD4+ T cells did not produce interferon gamma (IFNgamma) and IFNgamma-inducible protein 10 (IP-10) but were capable of proliferation upon stimulation with dendritic cells (DCs) loaded with an OCT4-derived peptide or OCT4 mRNA. OCT4-reactive CD8+ cells did not proliferate in response to a similar challenge, yet produced IP-10 as well as sufficient amounts of IFNgamma to induce IP-10 . Furthermore, CD8+ cytotoxic T cells were able to release their lysosomal components, as indicated by the mobilization of CD107a. These results demonstrate the existence of anti-CSC specific T cells in ovarian cancer patients.
This item appears in the following Collection(s)
- Academic publications [238441]
- Faculty of Medical Sciences [90373]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.